Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10885687 | PMC |
http://dx.doi.org/10.1016/j.hrcr.2023.11.003 | DOI Listing |
Aim: To assess the safety and efficacy of alfapump on ascites control and quality of life in these patients.
Methods: Patients with cirrhosis and RA requiring ≥2 TPs 30 days prior were enrolled and followed for 24 months (M) post-implant. Primary efficacy endpoint assessed at 6M was reduction in paracentesis requirement; safety end point was device related adverse events resulting in intervention, explant, or death.
J Heart Lung Transplant
December 2024
Department of Cardiac Surgery, Michigan Medicine, Ann Arbor, Michigan. Electronic address:
Background: Device-related infection (DRI) remains a cause of morbidity and mortality following durable left ventricular assist device (dLVAD) implantation. We evaluated outcomes following pump exchange (PE) for DRI following dLVAD implantation.
Methods: Forty-nine patients underwent PE between 1/2007 and 12/2022 for major DRI.
JACC Adv
December 2024
Section of Clinical Cardiac Electrophysiology, Department of Cardiovascular Medicine, Heart, Vascular and Thoracic Institute, Cleveland Clinic, Cleveland, Ohio, USA.
Background: Catheter ablation is an effective therapy in the management of atrial fibrillation (AF). Left atrial appendage closure (LAAC) is an alternative to anticoagulation for stroke prevention in patients with bleeding risks.
Objectives: The purpose of this study was to assess the safety and efficacy of combining AF ablation and LAAC in a single procedure.
J Surg Case Rep
November 2024
Surgical Research Section, Department of Surgery, Hamad Medical Corporation, 3050, Doha, Qatar.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!